Cite
HARVARD Citation
Overman, M. et al. (2020). Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal for immunotherapy of cancer. 8 (1), p. . [Online].